Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to
investigate the efficacy, safety and tolerability of intravenous balixafortide given with
eribulin versus eribulin alone in the treatment of HER2 negative, Locally Recurrent or
Metastatic Breast Cancer.